The sale for 14 million of a significant part of the activities to Neurosterix, however, allows the Geneva laboratory to stay afloat over the first three cumulative partials.
The Addex Therapeutics laboratory fell back into the red figures in the third quarter, in the wake of an unprecedented gain in the previous partial. The sale for 14.0 million francs of a significant part of the activities to Neurosterix allows the Plan-les-Ouatienne company to stay afloat for the first three cumulative partials.
The loss between July and the end of September amounts to 1.5 million francs, according to provisional figures communicated on Monday. Over the first nine months of 2024, Addex, on the other hand, posted a net profit of 8.3 million, compared to a loss of 9.8 million.
The developer of allosteric modulators warns, however, that the deficits will add up in the next partials. At the end of September, its cash reserves still stood at 3.3 million, compared to 3.6 million three months earlier.
The publication of detailed results is scheduled for November 22.
Business
